These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 9428495)

  • 1. Elevated levels of telomerase activity in malignant pheochromocytoma.
    Kubota Y; Nakada T; Sasagawa I; Yanai H; Itoh K
    Cancer; 1998 Jan; 82(1):176-9. PubMed ID: 9428495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
    Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
    Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
    Brown HM; Komorowski RA; Wilson SD; Demeure MJ; Zhu YR
    Cancer; 1999 Oct; 86(8):1583-9. PubMed ID: 10526289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase activity in benign and malignant adrenal tumors.
    Bamberger CM; Else T; Bamberger AM; Frilling A; Beil FU; Allolio B; Schulte HM
    Exp Clin Endocrinol Diabetes; 1999; 107(4):272-5. PubMed ID: 10433067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of telomerase for the diagnosis of malignant well-differentiated endocrine tumours.
    Vezzosi D; Bouisson M; Escourrou G; Laurell H; Selves J; Seguin P; Pradayrol L; Caron P; Buscail L
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):63-7. PubMed ID: 16402930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase activity as prognostic factor in gastrointestinal stromal tumors of the stomach.
    Kawai J; Kodera Y; Fujiwara M; Kasai Y; Nagasaka T; Koike M; Hibi K; Ito K; Akiyama S; Nakao A
    Hepatogastroenterology; 2005; 52(63):959-64. PubMed ID: 15966241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
    Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
    Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma.
    Boltze C; Mundschenk J; Unger N; Schneider-Stock R; Peters B; Mawrin C; Hoang-Vu C; Roessner A; Lehnert H
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4280-6. PubMed ID: 12970299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remarkably suppressed manganese superoxide dismutase activity in malignant pheochromocytoma.
    Nakada T; Kubota Y; Sasagawa I; Yagisawa T; Watanabe M; Ishigooka M
    J Urol; 1995 Jun; 153(6):1787-90. PubMed ID: 7752317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets.
    Meyer-Rochow GY; Jackson NE; Conaglen JV; Whittle DE; Kunnimalaiyaan M; Chen H; Westin G; Sandgren J; Stålberg P; Khanafshar E; Shibru D; Duh QY; Clark OH; Kebebew E; Gill AJ; Clifton-Bligh R; Robinson BG; Benn DE; Sidhu SB
    Endocr Relat Cancer; 2010 Sep; 17(3):835-46. PubMed ID: 20621999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas.
    Shen WT; Sturgeon C; Clark OH; Duh QY; Kebebew E
    Surgery; 2004 Dec; 136(6):1129-37. PubMed ID: 15657566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
    Feng C; Li HZ; Yan WG; Gao JG; Xu WF; Luo YF; Cao JL
    Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(24):1697-700. PubMed ID: 18476530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric DNA analysis for the determination of malignant potential in adrenal and extra-adrenal pheochromocytomas or paragangliomas.
    Pang LC; Tsao KC
    Arch Pathol Lab Med; 1993 Nov; 117(11):1142-7. PubMed ID: 8239937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.
    Suh I; Shibru D; Eisenhofer G; Pacak K; Duh QY; Clark OH; Kebebew E
    Ann Surg; 2009 Dec; 250(6):983-90. PubMed ID: 19661783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic management of benign and malignant pheochromocytoma.
    Scholz T; Schulz C; Klose S; Lehnert H
    Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):155-9. PubMed ID: 17427102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stathmin as a marker for malignancy in pheochromocytomas.
    Björklund P; Cupisti K; Fryknäs M; Isaksson A; Willenberg HS; Akerström G; Hellman P; Westin G
    Exp Clin Endocrinol Diabetes; 2010 Jan; 118(1):27-30. PubMed ID: 19449284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.
    Guillemot J; Thouënnon E; Guérin M; Vallet-Erdtmann V; Ravni A; Montéro-Hadjadje M; Lefebvre H; Klein M; Muresan M; Seidah NG; Anouar Y; Yon L
    J Mol Endocrinol; 2012 Apr; 48(2):115-27. PubMed ID: 22217803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of immunohistochemistry in histopathological diagnostics of clinically "silent" incidentally detected adrenal masses.
    Babinska A; Sworczak K; Wisniewski P; Nałecz A; Jaskiewicz K
    Exp Clin Endocrinol Diabetes; 2008 Apr; 116(4):246-51. PubMed ID: 18393131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microarray analysis reveals differential expression of benign and malignant pheochromocytoma.
    Waldmann J; Fendrich V; Holler J; Buchholz M; Heinmöller E; Langer P; Ramaswamy A; Samans B; Walz MK; Rothmund M; Bartsch DK; Slater EP
    Endocr Relat Cancer; 2010 Sep; 17(3):743-56. PubMed ID: 20562231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours.
    Uemura K; Hiyama E; Murakami Y; Kanehiro T; Ohge H; Sueda T; Yokoyama T
    Oncol Rep; 2003; 10(2):277-83. PubMed ID: 12579258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.